Sian Bigora

Sian Bigora, listed as senior executive, appears in our data through filings on Processa Pharmaceuticals, Inc. shares, published by SEC (Form 4). Between 5 August 2021 and 30 April 2026, the trades on record add up to 9 filings.

On the market, this insider has only ever bought: 3 purchases, €14k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant and 5 option exercises. 2026 to date brings 3 purchases and no sales.

A typical purchase (the median) is worth €4,555. 3 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 1 May 2026: an open-market purchase of €4,555, in Processa Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.